Symbols / CRBP
CRBP Chart
About
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 133.93M |
| Enterprise Value | 32.00M | Income | -67.51M | Sales | — |
| Book/sh | 7.35 | Cash/sh | 5.92 | Dividend Yield | — |
| Payout | 0.00% | Employees | 28 | IPO | — |
| P/E | — | Forward P/E | -1.48 | PEG | — |
| P/S | — | P/B | 1.04 | P/C | — |
| EV/EBITDA | -0.42 | EV/Sales | — | Quick Ratio | 6.09 |
| Current Ratio | 6.30 | Debt/Eq | 2.22 | LT Debt/Eq | — |
| EPS (ttm) | -5.68 | EPS next Y | -5.15 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-10 | ROA | -34.69% |
| ROE | -55.65% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 17.55M |
| Shs Float | 12.83M | Short Float | 8.85% | Short Ratio | 7.72 |
| Short Interest | — | 52W High | 20.56 | 52W Low | 4.64 |
| Beta | 2.85 | Avg Volume | 276.76K | Volume | 87.01K |
| Target Price | $42.33 | Recom | Strong_buy | Prev Close | $7.42 |
| Price | $7.63 | Change | 2.83% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$42.33
Mean price target
2. Current target
$7.63
Latest analyst target
3. DCF / Fair value
$-38.42
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$7.63
Low
$28.00
High
$53.00
Mean
$42.33
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-13 | main | RBC Capital | Outperform → Outperform | $53 |
| 2025-10-20 | main | Wedbush | Outperform → Outperform | $38 |
| 2025-10-20 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-09-17 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-08-06 | main | Oppenheimer | Outperform → Outperform | $53 |
| 2025-05-07 | main | RBC Capital | Outperform → Outperform | $58 |
| 2025-05-07 | main | Oppenheimer | Outperform → Outperform | $56 |
| 2025-05-07 | main | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-03-12 | reit | HC Wainwright & Co. | Buy → Buy | $50 |
| 2025-03-11 | main | Jefferies | Buy → Buy | $53 |
| 2025-02-28 | init | William Blair | — → Outperform | — |
| 2025-02-18 | reit | HC Wainwright & Co. | Buy → Buy | $75 |
| 2025-02-10 | reit | HC Wainwright & Co. | Buy → Buy | $75 |
| 2024-12-02 | init | Piper Sandler | — → Overweight | $35 |
| 2024-08-07 | reit | RBC Capital | Outperform → Outperform | $82 |
| 2024-08-07 | main | Oppenheimer | Outperform → Outperform | $88 |
| 2024-08-06 | reit | HC Wainwright & Co. | Buy → Buy | $80 |
| 2024-07-10 | reit | Oppenheimer | Outperform → Outperform | $80 |
| 2024-06-26 | init | B. Riley Securities | — → Buy | $85 |
| 2024-06-11 | main | RBC Capital | Outperform → Outperform | $82 |
- $CRBP stock is down 9% today. Here's what we see in our data. - Quiver Quantitative ue, 16 Dec 2025 08
- Corbus Pharma (Nasdaq: CRBP) prices $75M offering with pre-funded warrants, 30-day option - Stock Titan Fri, 31 Oct 2025 07
- While hedge funds own 24% of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), retail investors are its largest shareholders with 46% ownership - Yahoo Finance Sat, 27 Dec 2025 08
- CRBP Stock Surged 36% Pre-Market – What Did Its Obesity Treatment Drug Study Reveal? - Stocktwits hu, 11 Dec 2025 08
- (CRBP) and the Role of Price-Sensitive Allocations - Stock Traders Daily Wed, 18 Feb 2026 00
- Corbus Pharmaceuticals stock plunges after $75 million public offering - Investing.com Fri, 31 Oct 2025 07
- While institutions invested in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) benefited from last week's 12% gain, individual investors stood to gain the most - simplywall.st ue, 27 Jan 2026 08
- Corbus Pharmaceuticals: Data Update And Fundraising Efforts Do Not Diminish The Thesis - Seeking Alpha Wed, 05 Nov 2025 08
- Wall Street Analysts See a 764.18% Upside in Corbus Pharmaceuticals (CRBP): Can the Stock Really Move This High? - Nasdaq Fri, 18 Apr 2025 07
- Corbus Pharmaceuticals (CRBP) Sees Increased Price Target from W - GuruFocus Mon, 20 Oct 2025 07
- Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference - GlobeNewswire hu, 12 Feb 2026 08
- Corbus Pharma (NASDAQ: CRBP) to offer common stock, pre-funded warrants; 15% option - Stock Titan hu, 30 Oct 2025 07
- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is largely controlled by institutional shareholders who own 51% of the company - Yahoo Finance Sun, 20 Jul 2025 07
- Insider Sale: Chief Executive Officer of $CRBP Sells 8,973 Shares | CRBP Stock News - Quiver Quantitative Mon, 27 Oct 2025 07
- Corbus Pharmaceuticals: Downgrade To Hold Due To Narrow Focus Window (NASDAQ:CRBP) - Seeking Alpha Fri, 31 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 847 | 6253 | — | Sale at price 7.38 per share. | HODGSON IAN | Chief Operating Officer | — | 2026-02-17 00:00:00 | D |
| 1 | 13871 | 107952 | — | Sale at price 7.78 per share. | COHEN YUVAL | Chief Executive Officer | — | 2026-02-13 00:00:00 | D |
| 2 | 4701 | 36588 | — | Sale at price 7.78 per share. | MORAN SEAN F | Chief Financial Officer | — | 2026-02-13 00:00:00 | D |
| 3 | 3285 | 26575 | — | Sale at price 8.09 per share. | SMETHURST DOMINIC | Officer | — | 2026-02-03 00:00:00 | D |
| 4 | 2415 | 19537 | — | Sale at price 8.09 per share. | HODGSON IAN | Chief Operating Officer | — | 2026-02-03 00:00:00 | D |
| 5 | 50000 | — | — | Stock Award(Grant) at price 0.00 per share. | COHEN YUVAL | Chief Executive Officer | — | 2026-01-14 00:00:00 | D |
| 6 | 28365 | — | — | Stock Award(Grant) at price 0.00 per share. | SMETHURST DOMINIC | Officer | — | 2026-01-14 00:00:00 | D |
| 7 | 28365 | — | — | Stock Award(Grant) at price 0.00 per share. | HODGSON IAN | Chief Operating Officer | — | 2026-01-14 00:00:00 | D |
| 8 | 28082 | — | — | Stock Award(Grant) at price 0.00 per share. | MORAN SEAN F | Chief Financial Officer | — | 2026-01-14 00:00:00 | D |
| 9 | 30029 | 344012 | — | Sale at price 11.46 per share. | CORMORANT ASSET MANAGEMENT ,L.P | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-11 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -37.75M | -40.10M | -28.74M | -54.63M |
| TotalUnusualItems | 8.52K | -5.33M | 279.09K | |
| TotalUnusualItemsExcludingGoodwill | 8.52K | -5.33M | 279.09K | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -40.21M | -44.60M | -42.35M | -45.64M |
| ReconciledDepreciation | 588.00K | 641.00K | 763.00K | 1.64M |
| EBITDA | -37.75M | -40.10M | -34.07M | -54.35M |
| EBIT | -38.34M | -40.75M | -34.84M | -55.99M |
| NetInterestIncome | 4.44M | -2.22M | -2.13M | -1.83M |
| InterestExpense | 1.87M | 3.86M | ||
| InterestIncome | 6.31M | 1.64M | ||
| NormalizedIncome | -40.21M | -44.60M | -37.02M | -45.92M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -40.21M | -44.60M | -42.35M | -45.64M |
| TotalExpenses | 48.72M | 45.08M | 34.84M | 56.87M |
| TotalOperatingIncomeAsReported | -48.72M | -45.08M | -39.84M | -55.99M |
| DilutedAverageShares | 10.92M | 4.33M | 4.17M | 4.10M |
| BasicAverageShares | 10.92M | 4.33M | 4.17M | 4.10M |
| DilutedEPS | -3.68 | -10.31 | -10.15 | -11.10 |
| BasicEPS | -3.68 | -10.31 | -10.15 | -11.10 |
| DilutedNIAvailtoComStockholders | -40.21M | -44.60M | -42.35M | -45.64M |
| NetIncomeCommonStockholders | -40.21M | -44.60M | -42.35M | -45.64M |
| NetIncome | -40.21M | -44.60M | -42.35M | -45.64M |
| NetIncomeIncludingNoncontrollingInterests | -40.21M | -44.60M | -42.35M | -45.64M |
| NetIncomeContinuousOperations | -40.21M | -44.60M | -42.35M | -45.64M |
| PretaxIncome | -40.21M | -44.60M | -42.35M | -45.64M |
| OtherIncomeExpense | 4.07M | 2.70M | -5.38M | 12.18M |
| OtherNonOperatingIncomeExpenses | 4.07M | 2.70M | -48.77K | 11.90M |
| SpecialIncomeCharges | 0.00 | -5.00M | 0.00 | |
| OtherSpecialCharges | 5.00M | |||
| GainOnSaleOfSecurity | 8.52K | -330.59K | 279.09K | |
| NetNonOperatingInterestIncomeExpense | 4.44M | -2.22M | -2.13M | -1.83M |
| TotalOtherFinanceCost | 2.92M | 2.13M | 1.83M | |
| InterestExpenseNonOperating | 1.87M | 3.86M | ||
| InterestIncomeNonOperating | 6.31M | 1.64M | ||
| OperatingIncome | -48.72M | -45.08M | -34.84M | -55.99M |
| OperatingExpense | 48.72M | 45.08M | 34.84M | 56.87M |
| ResearchAndDevelopment | 32.22M | 31.17M | 16.14M | 36.45M |
| SellingGeneralAndAdministration | 16.50M | 13.91M | 18.70M | 20.43M |
| GeneralAndAdministrativeExpense | 16.50M | 13.91M | 18.70M | 20.43M |
| OtherGandA | 16.50M | 13.91M | 18.70M | 20.43M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 881.71K |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 881.71K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 12.18M | 4.42M | 4.17M | 4.17M |
| ShareIssued | 12.18M | 4.42M | 4.17M | 4.17M |
| NetDebt | 2.48M | 2.13M | ||
| TotalDebt | 3.24M | 20.89M | 25.09M | 26.59M |
| TangibleBookValue | 142.43M | -6.91M | 32.99M | 69.11M |
| InvestedCapital | 142.43M | 9.30M | 52.12M | 88.61M |
| WorkingCapital | 141.16M | -8.35M | 47.54M | 83.20M |
| NetTangibleAssets | 142.43M | -6.91M | 32.99M | 69.11M |
| CapitalLeaseObligations | 3.24M | 4.68M | 5.96M | 7.09M |
| CommonStockEquity | 142.43M | -6.91M | 32.99M | 69.11M |
| TotalCapitalization | 142.43M | -6.91M | 48.97M | 84.74M |
| TotalEquityGrossMinorityInterest | 142.43M | -6.91M | 32.99M | 69.11M |
| StockholdersEquity | 142.43M | -6.91M | 32.99M | 69.11M |
| GainsLossesNotAffectingRetainedEarnings | 35.00K | -1.00K | -126.09K | -62.45K |
| OtherEquityAdjustments | 35.00K | -1.00K | -126.09K | -62.45K |
| RetainedEarnings | -476.89M | -436.68M | -392.08M | -349.73M |
| AdditionalPaidInCapital | 619.28M | 429.78M | 425.20M | 418.90M |
| CapitalStock | 1.00K | 0.00 | 417.00 | 416.00 |
| CommonStock | 1.00K | 0.00 | 417.00 | 416.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 13.45M | 35.18M | 33.32M | 38.62M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.63M | 3.28M | 20.68M | 21.61M |
| OtherNonCurrentLiabilities | 44.00K | 22.20K | 22.20K | |
| LongTermDebtAndCapitalLeaseObligation | 1.63M | 3.24M | 20.66M | 21.59M |
| LongTermCapitalLeaseObligation | 1.63M | 3.24M | 4.68M | 5.96M |
| LongTermDebt | 15.98M | 15.64M | ||
| CurrentLiabilities | 11.82M | 31.89M | 12.64M | 17.01M |
| OtherCurrentLiabilities | 39.00K | 36.87K | 133.71K | |
| CurrentDebtAndCapitalLeaseObligation | 1.61M | 17.65M | 4.43M | 5.00M |
| CurrentCapitalLeaseObligation | 1.61M | 1.44M | 1.28M | 1.14M |
| CurrentDebt | 16.21M | 3.15M | 3.86M | |
| OtherCurrentBorrowings | 15.91M | 2.80M | 3.09M | |
| CurrentNotesPayable | 0.00 | 301.00K | 353.32K | 767.94K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.28M | 2.33M | 2.22M | 2.72M |
| PayablesAndAccruedExpenses | 7.94M | 14.21M | 5.95M | 9.16M |
| CurrentAccruedExpenses | 3.15M | 11.03M | 3.77M | 7.38M |
| InterestPayable | 0.00 | 1.34M | 916.11K | 525.11K |
| Payables | 4.79M | 3.18M | 2.17M | 1.78M |
| AccountsPayable | 4.79M | 3.18M | 2.17M | 1.78M |
| TotalAssets | 155.88M | 28.27M | 66.31M | 107.73M |
| TotalNonCurrentAssets | 2.90M | 4.73M | 6.13M | 7.53M |
| OtherNonCurrentAssets | 385.00K | 690.00K | 632.77K | 523.81K |
| NetPPE | 2.52M | 4.04M | 5.50M | 7.00M |
| AccumulatedDepreciation | -4.07M | -3.56M | -3.09M | -2.37M |
| GrossPPE | 6.59M | 7.59M | 8.59M | 9.37M |
| Leases | 3.33M | 3.33M | 3.33M | 3.33M |
| OtherProperties | 2.13M | 3.06M | 3.88M | 4.61M |
| MachineryFurnitureEquipment | 1.13M | 1.20M | 1.38M | 1.43M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 152.98M | 23.55M | 60.18M | 100.20M |
| OtherCurrentAssets | 3.63M | 2.45M | 791.62K | 2.37M |
| RestrictedCash | 285.00K | 192.00K | 192.47K | 192.47K |
| PrepaidAssets | 2.37M | |||
| Receivables | 0.00 | |||
| CashCashEquivalentsAndShortTermInvestments | 149.06M | 20.91M | 59.20M | 97.65M |
| OtherShortTermInvestments | 131.86M | 7.18M | 42.19M | 72.64M |
| CashAndCashEquivalents | 17.20M | 13.72M | 17.00M | 25.01M |
| CashEquivalents | 12.15M | 9.70M | 13.20M | 18.26M |
| CashFinancial | 5.05M | 4.03M | 3.81M | 6.75M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -41.79M | -36.10M | -37.56M | -48.24M |
| RepaymentOfDebt | -15.48M | -3.25M | -2.37M | -926.60K |
| IssuanceOfDebt | 0.00 | 373.00K | 1.83M | 984.38K |
| IssuanceOfCapitalStock | 182.06M | 53.00K | 0.00 | 62.59M |
| CapitalExpenditure | -13.45K | -54.17K | ||
| InterestPaidSupplementalData | 2.82M | 2.61M | 1.97M | 1.74M |
| EndCashPosition | 17.87M | 14.39M | 17.67M | 25.68M |
| BeginningCashPosition | 14.39M | 17.67M | 25.68M | 86.45M |
| ChangesInCash | 3.47M | -3.28M | -8.00M | -60.78M |
| FinancingCashFlow | 166.58M | -2.82M | -533.62K | 60.82M |
| CashFlowFromContinuingFinancingActivities | 166.58M | -2.82M | -533.62K | 60.82M |
| NetOtherFinancingCharges | -190.90K | -1.82M | ||
| NetCommonStockIssuance | 182.06M | 53.00K | 0.00 | 62.59M |
| CommonStockIssuance | 182.06M | 53.00K | 0.00 | 62.59M |
| NetIssuancePaymentsOfDebt | -15.48M | -2.87M | -533.62K | 57.78K |
| NetShortTermDebtIssuance | -52.66K | -414.62K | 57.78K | |
| ShortTermDebtPayments | -425.98K | -866.87K | -926.60K | |
| ShortTermDebtIssuance | 373.32K | 452.25K | 984.38K | |
| NetLongTermDebtIssuance | -15.48M | -2.87M | -119.00K | 0.00 |
| LongTermDebtPayments | -15.48M | -3.25M | -1.50M | 0.00 |
| LongTermDebtIssuance | 0.00 | 373.00K | 1.38M | 0.00 |
| InvestingCashFlow | -121.31M | 35.64M | 30.07M | -73.42M |
| CashFlowFromContinuingInvestingActivities | -121.31M | 35.64M | 30.07M | -73.42M |
| NetInvestmentPurchaseAndSale | -121.31M | 35.64M | 30.08M | -73.39M |
| SaleOfInvestment | 59.49M | 69.53M | 116.42M | 13.88M |
| PurchaseOfInvestment | -180.80M | -33.88M | -86.34M | -87.27M |
| NetPPEPurchaseAndSale | 0.00 | -5.35K | -30.27K | |
| SaleOfPPE | 0.00 | 8.10K | 23.90K | |
| PurchaseOfPPE | 0.00 | -13.45K | -54.17K | |
| OperatingCashFlow | -41.79M | -36.10M | -37.54M | -48.18M |
| CashFlowFromContinuingOperatingActivities | -41.79M | -36.10M | -37.54M | -48.18M |
| ChangeInWorkingCapital | -5.58M | 4.09M | -3.30M | -15.70M |
| ChangeInOtherWorkingCapital | 22.20K | |||
| ChangeInOtherCurrentLiabilities | -1.48M | -1.26M | -1.14M | -981.86K |
| ChangeInOtherCurrentAssets | 1.14M | 764.00K | 615.90K | 187.65K |
| ChangeInPayablesAndAccruedExpense | -4.01M | 6.06M | -4.35M | -17.87M |
| ChangeInAccruedExpense | -5.61M | 5.03M | -4.09M | -11.91M |
| ChangeInPayable | 1.60M | 1.03M | -256.83K | -5.96M |
| ChangeInAccountPayable | 1.60M | 1.03M | -256.83K | -5.96M |
| ChangeInPrepaidAssets | -1.23M | -1.47M | 1.57M | 1.35M |
| ChangeInReceivables | 0.00 | 1.62M | ||
| OtherNonCashItems | 585.00K | 805.00K | 742.48K | 950.61K |
| StockBasedCompensation | 6.14M | 3.47M | 5.72M | 9.48M |
| AssetImpairmentCharge | 0.00 | 606.08K | ||
| AmortizationOfSecurities | -3.33M | -506.00K | 124.88K | 698.25K |
| DepreciationAmortizationDepletion | 588.00K | 641.00K | 763.00K | 1.64M |
| DepreciationAndAmortization | 588.00K | 641.00K | 763.00K | 1.64M |
| Depreciation | 588.00K | 641.00K | 1.49M | 1.64M |
| OperatingGainsLosses | -20.43K | 751.13K | -221.35K | |
| GainLossOnInvestmentSecurities | 3.29K | 81.38K | -663.29K | |
| NetForeignCurrencyExchangeGainLoss | -23.73K | 648.52K | 342.42K | |
| GainLossOnSaleOfPPE | 0.00 | 21.23K | 99.52K | |
| NetIncomeFromContinuingOperations | -40.21M | -44.60M | -42.35M | -45.64M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CRBP
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|